论文信息 - KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). - 字舞流文

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil | K. Harrington | A. Psyrri | D. Rischin | B. Burtness | N. Ngamphaiboon | B. Hughes | R. Mesía | A. Bratland | D. Soulières | G. de Castro | T. Fuereder | M. Tahara | N. Basté Rotllán | P. Neupane | T. Rordorf | W. Z. Wan Ishak | A. Roy | J. Cheng | F. Jin | W. Z. W. Ishak | G. Castro | J. Cheng | N. B. Rotllán | Denis Soulières | Makoto Tahara | R. Greil | B. Hughes | D. Rischin | Fan Jin | Jonathan D. Cheng | A. Psyrri